MedTrace Logo

Endoscopic Remission, Histologic Remission and Barrier Healing for Predicting Disease Behaviour in IBD

NCT05157750 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 180

Last updated 2021-12-15

No results posted yet for this study

Summary

Within this study, the investigators aim to directly compare the value of endoscopic remission, histologic remission and barrier healing for predicting long-term disease behavior in a large cohort of clinically remittent IBD patients.

Conditions

  • Inflammatory Bowel Diseases

Interventions

OTHER

Recording of major clinical events

During follow-up, major clinical events, defined as (i) disease flare; (ii) IBD-related hospitalization, (iii) IBD-related surgery, (iv) necessity for initiation of systemic steroids, immunosuppressants or biologics; (v) necessity for escalation of an existing biological therapy, will be recorded.

Sponsors & Collaborators

  • University of Erlangen-Nürnberg Medical School

    lead OTHER

Principal Investigators

  • Timo Rath, MD · University Hospital Erlangen, Department of Medicine 1

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-16
Primary Completion
2022-04-01
Completion
2022-05-01

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05157750 on ClinicalTrials.gov